Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Colorectal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Solid Tumor (16201
)
Colon Cancer (169
)
Rectal Cancer (89
)
Colorectal Adenocarcinoma (9
)
Solid Tumor (16201
)
Colon Cancer (169
)
Rectal Cancer (89
)
Colorectal Adenocarcinoma (9
)
›
Associations
(1343)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
HER-2 positive
Colorectal Cancer
HER-2 positive
Colorectal Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
Chugai Press Release - 3 days (New A1)
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
Chugai Press Release - 3d
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
Chugai Press Release - 3 days
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
Chugai Press Release - 3 days - (New A1)
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
panitumumab + sotorasib
Sensitive
:
A2
NCCN - 1wk
panitumumab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week
panitumumab + sotorasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
cetuximab + sotorasib
Sensitive
:
A2
NCCN - 1wk
cetuximab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week
cetuximab + sotorasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
panitumumab + adagrasib
Sensitive
:
A2
NCCN - 1wk
panitumumab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week
panitumumab + adagrasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
cetuximab + adagrasib
Sensitive
:
A2
NCCN - 1wk
cetuximab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week
cetuximab + adagrasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
panitumumab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
panitumumab + sotorasib
Sensitive
:
A2
NCCN - 1wk
panitumumab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week
panitumumab + sotorasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
cetuximab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
cetuximab + sotorasib
Sensitive
:
A2
NCCN - 1wk
cetuximab + sotorasib
Sensitive: A2 - Guideline
NCCN - 1 week
cetuximab + sotorasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
panitumumab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
panitumumab + adagrasib
Sensitive
:
A2
NCCN - 1wk
panitumumab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week
panitumumab + adagrasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
NICE - 1 week (New A2)
pembrolizumab
Sensitive
:
A1
NICE - 1wk
pembrolizumab
Sensitive: A1 - Approval
NICE - 1 week
pembrolizumab
Sensitive
:
A1
NICE - 1 week - (New A2)
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
cetuximab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
cetuximab + adagrasib
Sensitive
:
A2
NCCN - 1wk
cetuximab + adagrasib
Sensitive: A2 - Guideline
NCCN - 1 week
cetuximab + adagrasib
Sensitive
:
A2
NCCN - 1 week - (New A2)
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
J Geriatr Oncol - 1 week (New C3)
bevacizumab
Sensitive
:
C2
J Geriatr Oncol - 1wk
bevacizumab
Sensitive: C2 – Inclusion Criteria
J Geriatr Oncol - 1 week
bevacizumab
Sensitive
:
C2
J Geriatr Oncol - 1 week - (New C3)
RAS wild-type + BRAF wild-type
Colorectal Cancer
RAS wild-type + BRAF wild-type
Colorectal Cancer
cetuximab
Sensitive: C2 – Inclusion Criteria
Med Princ Pract - 1 week (New C3)
cetuximab
Sensitive
:
C2
Med Princ Pract - 1wk
cetuximab
Sensitive: C2 – Inclusion Criteria
Med Princ Pract - 1 week
cetuximab
Sensitive
:
C2
Med Princ Pract - 1 week - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week (New C3)
Immunotherapy
Sensitive
:
C3
Clin Cancer Res - 1wk
Immunotherapy
Sensitive: C3 – Early Trials
Clin Cancer Res - 1 week
Immunotherapy
Sensitive
:
C3
Clin Cancer Res - 1 week - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
ramucirumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks (New C3)
ramucirumab
Sensitive
:
C2
ESMO Open - 2wk
ramucirumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks
ramucirumab
Sensitive
:
C2
ESMO Open - 2 weeks - (New C3)
miR-18a overexpression
Colorectal Cancer
miR-18a overexpression
Colorectal Cancer
FOLFOX
Sensitive: C3 – Early Trials
Cancer Rep (Hoboken) - 2 weeks (New C3)
FOLFOX
Sensitive
:
C3
Cancer Rep (Hoboken) - 2wk
FOLFOX
Sensitive: C3 – Early Trials
Cancer Rep (Hoboken) - 2 weeks
FOLFOX
Sensitive
:
C3
Cancer Rep (Hoboken) - 2 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
bevacizumab
Sensitive: B - Late Trials
Nat Commun - 3 weeks (New B)
bevacizumab
Sensitive
:
B
Nat Commun - 3wk
bevacizumab
Sensitive: B - Late Trials
Nat Commun - 3 weeks
bevacizumab
Sensitive
:
B
Nat Commun - 3 weeks - (New B)
KRAS wild-type
Colorectal Cancer
KRAS wild-type
Colorectal Cancer
cetuximab
Sensitive: B - Late Trials
Nat Commun - 3 weeks (New B)
cetuximab
Sensitive
:
B
Nat Commun - 3wk
cetuximab
Sensitive: B - Late Trials
Nat Commun - 3 weeks
cetuximab
Sensitive
:
B
Nat Commun - 3 weeks - (New B)
BRAF wild-type
Colorectal Cancer
BRAF wild-type
Colorectal Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
Front Oncol - 3 weeks (New C3)
anlotinib
Sensitive
:
C2
Front Oncol - 3wk
anlotinib
Sensitive: C2 – Inclusion Criteria
Front Oncol - 3 weeks
anlotinib
Sensitive
:
C2
Front Oncol - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
anlotinib
Sensitive: C3 – Early Trials
Front Oncol - 3 weeks (New C3)
anlotinib
Sensitive
:
C3
Front Oncol - 3wk
anlotinib
Sensitive: C3 – Early Trials
Front Oncol - 3 weeks
anlotinib
Sensitive
:
C3
Front Oncol - 3 weeks - (New C3)
RAS mutation
Colorectal Cancer
RAS mutation
Colorectal Cancer
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
Oncology - 3 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
Oncology - 3wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
Oncology - 3 weeks
durvalumab + tremelimumab
Sensitive
:
C3
Oncology - 3 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
FOLFIRI
Sensitive: A1 - Approval
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
bevacizumab-bvzr
Resistant: A1 - Approval
bevacizumab-bvzr
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
ziv-aflibercept IV
Sensitive: A1 - Approval
ziv-aflibercept IV
Sensitive
:
A1
ziv-aflibercept IV
Sensitive: A1 - Approval
ziv-aflibercept IV
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
EGFR expression
Colorectal Cancer
EGFR expression
Colorectal Cancer
cetuximab
Sensitive: A1 - Approval
cetuximab
Sensitive
:
A1
cetuximab
Sensitive: A1 - Approval
cetuximab
Sensitive
:
A1
KRAS Q61
Colorectal Cancer
KRAS Q61
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
KRAS A146
Colorectal Cancer
KRAS A146
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
irinotecan
Sensitive: A1 - Approval
irinotecan
Sensitive
:
A1
KRAS G13
Colorectal Cancer
KRAS G13
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS G12
Colorectal Cancer
KRAS G12
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
KRAS K117
Colorectal Cancer
KRAS K117
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS A59
Colorectal Cancer
KRAS A59
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
KRAS G12S
Colorectal Cancer
KRAS G12S
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
NRAS Q61
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
NRAS Q61
Colorectal Cancer
NRAS Q61
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
NRAS G13
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
NRAS G13
Colorectal Cancer
NRAS G13
Colorectal Cancer
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
cetuximab
Resistant: A1 - Approval
cetuximab
Resistant
:
A1
NRAS G12
Colorectal Cancer
NRAS G12
Colorectal Cancer
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
panitumumab
Resistant: A1 - Approval
panitumumab
Resistant
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login